• Login / Register
    View Item 
    •   Home
    • Support Departments
    • Harvested data
    • View Item
    •   Home
    • Support Departments
    • Harvested data
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChesterRepCommunitiesTitleAuthorsPublication DateSubmit DateSubjectsPublisherJournalThis CollectionTitleAuthorsPublication DateSubmit DateSubjectsPublisherJournalProfilesView

    My Account

    LoginRegister

    About

    AboutUniversity of Chester

    Statistics

    Display statistics

    Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    cancers-13-02155.xml
    Size:
    11.66Kb
    Format:
    XML
    Download
    Thumbnail
    Name:
    additional-files.zip
    Size:
    389.5Kb
    Format:
    Unknown
    Download
    Thumbnail
    Name:
    cancers-13-02155-v2.pdf
    Size:
    1.766Mb
    Format:
    PDF
    Download
    Authors
    Clark, Richard E.
    Basabrain, Ammar A.
    Austin, Gemma M.
    Holcroft, Alison K.
    Loaiza, Sandra
    Apperley, Jane F.
    Law, Christopher
    Scott, Laura
    Parry, Alexandra D.
    Bonnett, Laura
    Lucas, Claire M.
    Show allShow less
    Publication Date
    2021-04-29
    
    Metadata
    Show full item record
    Abstract
    Background: It would be clinically useful to prospectively identify the risk of disease progression in chronic myeloid leukaemia (CML). Overexpression of cancerous inhibitor of protein phosphatase 2A (PP2A) (CIP2A) protein is an adverse prognostic indicator in many cancers. Methods: We examined CIP2A protein levels in diagnostic samples from the SPIRIT2 trial in 172 unselected patients, of whom 90 received imatinib and 82 dasatinib as first-line treatment. Results: High CIP2A levels correlated with inferior progression-free survival (p = 0.04) and with worse freedom from progression (p = 0.03), and these effects were confined to dasatinib recipients. High CIP2A levels were associated with a six-fold higher five-year treatment failure rate than low CIP2A levels (41% vs. 7.5%; p = 0.0002), in both imatinib (45% vs. 11%; p = 0.02) and dasatinib recipients (36% vs. 4%; p = 0.007). Imatinib recipients with low CIP2A levels had a greater risk of treatment failure (p = 0.0008). CIP2A levels were independent of Sokal, Hasford, EUTOS (EUropean Treatment and Outcome Study), or EUTOS long-term survival scores (ELTS) or the presence of major route cytogenetic abnormalities. No association was seen between CIP2A levels and time to molecular response or the levels of the CIP2A-related proteins PP2A, SET, SET binding protein 1 (SETBP1), or AKT. Conclusions: These data confirm that high diagnostic CIP2A levels correlate with subsequent disease progression and treatment failure. CIP2A is a simple diagnostic biomarker that may be useful in planning treatment strategies.
    Citation
    Cancers, volume 13, issue 9, page e2155
    Publisher
    MDPI
    URI
    http://hdl.handle.net/10034/624488
    Type
    article
    Description
    From MDPI via Jisc Publications Router
    History: accepted 2021-04-01, pub-electronic 2021-04-29
    Publication status: Published
    Funder: Bristol-Myers Squibb; Grant(s): CA180 659
    Collections
    Harvested data

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.